FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281868085> ?p ?o ?g. }

• W4281868085 endingPage "3939" @default.
• W4281868085 startingPage "3939" @default.
• W4281868085 abstract "Laser-induced fluorescence is recently used as an efficient technique in cancer diagnosis and non-invasive treatment. Here, the synergic therapeutical efficacies of the Capecitabine (CAP) chemodrug, photosensitive Phycocyanin (PC) and graphene oxide (GO) under laser irradiation were investigated. The therapeutical efficacies of diverse concentrations of CAP (0.001-10 mg/ml) and PC (0.5-10 mg/ml) alone and with laser irradiation on human breast adenocarcinoma (MCF-7) cells were examined. The interactional effects of 100 mW SHG Nd:YAG laser at 532nm and GaAs laser at 808 nm ranging power of 150 mW- 2.2W were considered. The contribution of graphene oxide (GO) in biocompatible concentrations of 2.5-20 ng/ml and thermal characteristics of laser exposure at 808 nm on GO + fluorophores have been studied. The effects of the bare and laser-excited CAP + PC on cell mortality have been obtained. Despite the laser irradiation could not hold up the cell proliferation in the absence of drug interaction considerably; however, the viability of the treated cells (by a combination of fluorophores) under laser exposure at 808 nm was significantly reduced. The laser at 532 nm excited the fluorescent PC in (CAP + PC) to trigger the photodynamic processes via oxygen generation. Through the in-vitro experiments of laser-induced fluorescence (LIF) spectroscopy of PC + CAP, the PC/CAP concentrations of the maximum fluorescence signal and spectral shifts have been characterized. The synergic effects of the laser exposures and (CAP + PC) treatment at different concentrations were confirmed. It has been shown here that the laser activation of (CAP + PC) can induce the mortality of the malignant cells by reducing the chemotherapeutic dose of CAP to avoid its non-desirable side effects and by approaching the minimally invasive treatment. Elevation of the laser intensity/exposure time could contribute to the therapeutic efficacy. Survival of the treated cells with a combination of GO and fluorophores could be reduced under laser exposure at 808 nm compared to the same combination therapy in the absence of GO. This survey could benefit the forthcoming clinical protocols based on laser spectroscopy for in-situ imaging/diagnosis/treatment of adenocarcinoma utilizing PC + CAP + GO." @default.
• W4281868085 created "2022-06-13" @default.
• W4281868085 creator A5026234426 @default.
• W4281868085 creator A5043683721 @default.
• W4281868085 creator A5047972028 @default.
• W4281868085 creator A5069157906 @default.
• W4281868085 creator A5070950256 @default.
• W4281868085 creator A5076911989 @default.
• W4281868085 date "2022-06-16" @default.
• W4281868085 modified "2023-09-27" @default.
• W4281868085 title "Hybrid laser activated phycocyanin/capecitabine treatment of cancerous MCF7 cells" @default.
• W4281868085 cites W1192886117 @default.
• W4281868085 cites W1980419364 @default.
• W4281868085 cites W2032542278 @default.
• W4281868085 cites W2035250674 @default.
• W4281868085 cites W2044931307 @default.
• W4281868085 cites W2048400927 @default.
• W4281868085 cites W2049348590 @default.
• W4281868085 cites W2089746271 @default.
• W4281868085 cites W2089802020 @default.
• W4281868085 cites W2098143294 @default.
• W4281868085 cites W2107872107 @default.
• W4281868085 cites W2114500428 @default.
• W4281868085 cites W2189270998 @default.
• W4281868085 cites W2318967109 @default.
• W4281868085 cites W2333897814 @default.
• W4281868085 cites W2358685834 @default.
• W4281868085 cites W2400600528 @default.
• W4281868085 cites W2419563575 @default.
• W4281868085 cites W2422478002 @default.
• W4281868085 cites W2425882758 @default.
• W4281868085 cites W2465519026 @default.
• W4281868085 cites W2529389662 @default.
• W4281868085 cites W2531319618 @default.
• W4281868085 cites W2548549036 @default.
• W4281868085 cites W2562845452 @default.
• W4281868085 cites W2606220448 @default.
• W4281868085 cites W2625031879 @default.
• W4281868085 cites W2739107860 @default.
• W4281868085 cites W2742964199 @default.
• W4281868085 cites W2750468042 @default.
• W4281868085 cites W2751856377 @default.
• W4281868085 cites W2756555938 @default.
• W4281868085 cites W2765089738 @default.
• W4281868085 cites W2806674272 @default.
• W4281868085 cites W2915217532 @default.
• W4281868085 cites W2921150193 @default.
• W4281868085 cites W2945397666 @default.
• W4281868085 cites W2969561499 @default.
• W4281868085 cites W2981253705 @default.
• W4281868085 cites W2994198136 @default.
• W4281868085 cites W3001797168 @default.
• W4281868085 cites W3005223027 @default.
• W4281868085 cites W3024742999 @default.
• W4281868085 cites W3026333088 @default.
• W4281868085 cites W3034168361 @default.
• W4281868085 cites W3118081315 @default.
• W4281868085 cites W3178967475 @default.
• W4281868085 cites W3180784367 @default.
• W4281868085 cites W3202605179 @default.
• W4281868085 doi "https://doi.org/10.1364/boe.459737" @default.
• W4281868085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35991918" @default.
• W4281868085 hasPublicationYear "2022" @default.
• W4281868085 type Work @default.
• W4281868085 citedByCount "1" @default.
• W4281868085 countsByYear W42818680852023 @default.
• W4281868085 crossrefType "journal-article" @default.
• W4281868085 hasAuthorship W4281868085A5026234426 @default.
• W4281868085 hasAuthorship W4281868085A5043683721 @default.
• W4281868085 hasAuthorship W4281868085A5047972028 @default.
• W4281868085 hasAuthorship W4281868085A5069157906 @default.
• W4281868085 hasAuthorship W4281868085A5070950256 @default.
• W4281868085 hasAuthorship W4281868085A5076911989 @default.
• W4281868085 hasBestOaLocation W42818680851 @default.
• W4281868085 hasConcept C111337013 @default.
• W4281868085 hasConcept C120665830 @default.
• W4281868085 hasConcept C121332964 @default.
• W4281868085 hasConcept C178790620 @default.
• W4281868085 hasConcept C185544564 @default.
• W4281868085 hasConcept C185592680 @default.
• W4281868085 hasConcept C192562407 @default.
• W4281868085 hasConcept C2781323092 @default.
• W4281868085 hasConcept C2781469039 @default.
• W4281868085 hasConcept C520434653 @default.
• W4281868085 hasConcept C75473681 @default.
• W4281868085 hasConcept C91881484 @default.
• W4281868085 hasConceptScore W4281868085C111337013 @default.
• W4281868085 hasConceptScore W4281868085C120665830 @default.
• W4281868085 hasConceptScore W4281868085C121332964 @default.
• W4281868085 hasConceptScore W4281868085C178790620 @default.
• W4281868085 hasConceptScore W4281868085C185544564 @default.
• W4281868085 hasConceptScore W4281868085C185592680 @default.
• W4281868085 hasConceptScore W4281868085C192562407 @default.
• W4281868085 hasConceptScore W4281868085C2781323092 @default.
• W4281868085 hasConceptScore W4281868085C2781469039 @default.
• W4281868085 hasConceptScore W4281868085C520434653 @default.
• W4281868085 hasConceptScore W4281868085C75473681 @default.
• W4281868085 hasConceptScore W4281868085C91881484 @default.

• next